开云app官网登录入口网页版-官方正版

#EGFR TKI#

13篇内容 | 997人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2206615, encodeId=92fb22066158e, content=<a href='/topic/show?id=32af9938ec6' target=_blank style='color:#2F92EE;'>#非小细胞肺癌#</a> <a href='/topic/show?id=029e2901e8e' target=_blank style='color:#2F92EE;'>#免疫微环境#</a> <a href='/topic/show?id=cd5865e036' target=_blank style='color:#2F92EE;'>#EGFR TKI#</a> <a href='/topic/show?id=a11611291471' target=_blank style='color:#2F92EE;'>#EGFR T790M突变#</a>, objectTitle=【论著】| EGFR T790M突变非小细胞肺癌患者的临床病理学、免疫微环境特征及对预后预测的意义, objectType=article, longId=827507, objectId=bbeb82e507cb, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240525/1716651810126_92910.png, objectUrl=/article/show_article.do?id=bbeb82e507cb, replyNumber=0, likeNumber=94, createdTime=2024-05-26, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=bbeb82e507cb, moduleTitle=【论著】| EGFR T790M突变非小细胞肺癌患者的临床病理学、免疫微环境特征及对预后预测的意义, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=bbeb82e507cb)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2040487, encodeId=afdb204048eec, content=<a href='/topic/show?id=cd5865e036' target=_blank style='color:#2F92EE;'>#EGFR TKI#</a>, objectTitle=Lancet oncol：信迪利单抗+IBI305+化疗治疗EGFR TKI治疗后进展的EGFR突变型NSCLC, objectType=article, longId=734225, objectId=0acbe3422547, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0acbe3422547, replyNumber=0, likeNumber=83, createdTime=2023-03-09, rootId=0, userName=gao_jian4217, userId=c66088, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0acbe3422547, moduleTitle=Lancet oncol：信迪利单抗+IBI305+化疗治疗EGFR TKI治疗后进展的EGFR突变型NSCLC, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=0acbe3422547)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2040486, encodeId=9673204048620, content=<a href='/topic/show?id=cd5865e036' target=_blank style='color:#2F92EE;'>#EGFR TKI#</a>, objectTitle=豪森药业第三代EGFR TKI在中国获批用于EGFR T790M突变型非小细胞肺癌的二线治疗, objectType=article, longId=190514, objectId=8e2119051451, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8e2119051451, replyNumber=0, likeNumber=0, createdTime=2021-01-15, rootId=0, userName=gao_jian4217, userId=c66088, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8e2119051451, moduleTitle=豪森药业第三代EGFR TKI在中国获批用于EGFR T790M突变型非小细胞肺癌的二线治疗, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=8e2119051451)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2040484, encodeId=7f9520404846e, content=<a href='/topic/show?id=cd5865e036' target=_blank style='color:#2F92EE;'>#EGFR TKI#</a>, objectTitle=ASCO2019 |化疗优于EGFR TKI？中国晚期NSCLC EGFR 20外显子插入突变患者的真实世界治疗结果, objectType=article, longId=167660, objectId=579916e66023, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=579916e66023, replyNumber=0, likeNumber=92, createdTime=2019-10-12, rootId=0, userName=gao_jian4217, userId=c66088, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=579916e66023, moduleTitle=ASCO2019 |化疗优于EGFR TKI？中国晚期NSCLC EGFR 20外显子插入突变患者的真实世界治疗结果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=579916e66023)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2040485, encodeId=88df2040485d4, content=<a href='/topic/show?id=cd5865e036' target=_blank style='color:#2F92EE;'>#EGFR TKI#</a>, objectTitle=宋勇教授：如何驾驭EGFR TKI三匹宝马？, objectType=article, longId=169067, objectId=589e16906e20, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=589e16906e20, replyNumber=0, likeNumber=79, createdTime=2020-04-18, rootId=0, userName=gao_jian4217, userId=c66088, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=589e16906e20, moduleTitle=宋勇教授：如何驾驭EGFR TKI三匹宝马？, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=589e16906e20)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2040481, encodeId=761420404812a, content=<a href='/topic/show?id=cd5865e036' target=_blank style='color:#2F92EE;'>#EGFR TKI#</a>, objectTitle=何勇教授：第三代EGFR TKI奥希替尼的一线使用经验探讨, objectType=article, longId=155682, objectId=41eb155682eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=41eb155682eb, replyNumber=0, likeNumber=85, createdTime=2019-08-11, rootId=0, userName=gao_jian4217, userId=c66088, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=41eb155682eb, moduleTitle=何勇教授：第三代EGFR TKI奥希替尼的一线使用经验探讨, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=41eb155682eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2040483, encodeId=8840204048367, content=<a href='/topic/show?id=cd5865e036' target=_blank style='color:#2F92EE;'>#EGFR TKI#</a>, objectTitle=CLIN CANCER RES：MERTK抑制剂联合EGFR TKI治疗非小细胞肺癌, objectType=article, longId=156473, objectId=032c1564e304, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=032c1564e304, replyNumber=0, likeNumber=0, createdTime=2019-11-06, rootId=0, userName=gao_jian4217, userId=c66088, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=032c1564e304, moduleTitle=CLIN CANCER RES：MERTK抑制剂联合EGFR TKI治疗非小细胞肺癌, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=032c1564e304)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2040480, encodeId=7b112040480e9, content=<a href='/topic/show?id=cd5865e036' target=_blank style='color:#2F92EE;'>#EGFR TKI#</a>, objectTitle=【2018WCLC】逆转耐药，EGFR TKIs耐药后联用阿帕替尼的临床价值再探索, objectType=article, longId=150184, objectId=a0d515018464, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a0d515018464, replyNumber=0, likeNumber=98, createdTime=2018-10-27, rootId=0, userName=gao_jian4217, userId=c66088, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a0d515018464, moduleTitle=【2018WCLC】逆转耐药，EGFR TKIs耐药后联用阿帕替尼的临床价值再探索, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=a0d515018464)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2040479, encodeId=61fa20404e93f, content=<a href='/topic/show?id=cd5865e036' target=_blank style='color:#2F92EE;'>#EGFR TKI#</a>, objectTitle=Brit J Cancer：转移性肾细胞癌免疫组合治疗后VEGFR TKI治疗效果研究, objectType=article, longId=139220, objectId=46ac139220d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=46ac139220d5, replyNumber=0, likeNumber=75, createdTime=2018-08-02, rootId=0, userName=gao_jian4217, userId=c66088, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=46ac139220d5, moduleTitle=Brit J Cancer：转移性肾细胞癌免疫组合治疗后VEGFR TKI治疗效果研究, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=46ac139220d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2040482, encodeId=4c5f20404825c, content=<a href='/topic/show?id=cd5865e036' target=_blank style='color:#2F92EE;'>#EGFR TKI#</a>, objectTitle=韩宝惠教授：三代EGFR TKI奥希替尼防控肺癌脑转移效果显著, objectType=article, longId=155981, objectId=0cdf1559810c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0cdf1559810c, replyNumber=0, likeNumber=118, createdTime=2019-05-16, rootId=0, userName=gao_jian4217, userId=c66088, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0cdf1559810c, moduleTitle=韩宝惠教授：三代EGFR TKI奥希替尼防控肺癌脑转移效果显著, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=0cdf1559810c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2040477, encodeId=392020404e7c5, content=<a href='/topic/show?id=cd5865e036' target=_blank style='color:#2F92EE;'>#EGFR TKI#</a>, objectTitle=【CSCO看点】中国晚期NSCLC EGFR TKI耐药后T790M 突变率知多少？, objectType=article, longId=114385, objectId=e7721143856c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e7721143856c, replyNumber=0, likeNumber=75, createdTime=2018-02-26, rootId=0, userName=gao_jian4217, userId=c66088, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e7721143856c, moduleTitle=【CSCO看点】中国晚期NSCLC EGFR TKI耐药后T790M 突变率知多少？, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=e7721143856c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2040478, encodeId=3d1d20404e8b3, content=<a href='/topic/show?id=cd5865e036' target=_blank style='color:#2F92EE;'>#EGFR TKI#</a>, objectTitle=[WCLC2017]大咖圆桌会：多学科专家共话肺癌EGFR TKI靶向治疗热点, objectType=article, longId=118378, objectId=d0071183e824, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d0071183e824, replyNumber=0, likeNumber=73, createdTime=2018-08-25, rootId=0, userName=gao_jian4217, userId=c66088, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d0071183e824, moduleTitle=[WCLC2017]大咖圆桌会：多学科专家共话肺癌EGFR TKI靶向治疗热点, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=d0071183e824)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2040476, encodeId=e10120404e637, content=<a href='/topic/show?id=cd5865e036' target=_blank style='color:#2F92EE;'>#EGFR TKI#</a>, objectTitle=T790M突变检测，实现EGFR TKI耐药患者的精准治疗, objectType=article, longId=108175, objectId=29721081e5ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=29721081e5ad, replyNumber=0, likeNumber=72, createdTime=2018-04-16, rootId=0, userName=gao_jian4217, userId=c66088, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=29721081e5ad, moduleTitle=T790M突变检测，实现EGFR TKI耐药患者的精准治疗, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=29721081e5ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2040475, encodeId=c0f320404e511, content=<a href='/topic/show?id=cd5865e036' target=_blank style='color:#2F92EE;'>#EGFR TKI#</a>, objectTitle=JCO：香港中文大学莫树锦对比分析EGFR TKI药物一二线治疗情况, objectType=article, longId=19401, objectId=650819401a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=650819401a2, replyNumber=0, likeNumber=101, createdTime=2013-11-04, rootId=0, userName=gao_jian4217, userId=c66088, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=650819401a2, moduleTitle=JCO：香港中文大学莫树锦对比分析EGFR TKI药物一二线治疗情况, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=650819401a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

EGFR TKI

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#非小细胞肺癌# #免疫微环境# #EGFR TKI# #EGFR T790M突变#

【论著】| EGFR T790M突变非小细胞肺癌患者的临床病理学、免疫微环境特征及对预后预测的意义

2024-05-26发表于上海

gao_jian4217 (审核中...)

前往app查看评论内容

#EGFR TKI#

Lancet oncol：信迪利单抗+IBI305+化疗治疗EGFR TKI治疗后进展的EGFR突变型NSCLC

2023-03-09

gao_jian4217 (审核中...)

前往app查看评论内容

#EGFR TKI#

豪森药业第三代EGFR TKI在中国获批用于EGFR T790M突变型非小细胞肺癌的二线治疗

2021-01-15

gao_jian4217 (审核中...)

前往app查看评论内容

#EGFR TKI#

ASCO2019 |化疗优于EGFR TKI？中国晚期NSCLC EGFR 20外显子插入突变患者的真实世界治疗结果

2019-10-12

gao_jian4217 (审核中...)

前往app查看评论内容

#EGFR TKI#

宋勇教授：如何驾驭EGFR TKI三匹宝马？

2020-04-18

gao_jian4217 (审核中...)

前往app查看评论内容

#EGFR TKI#

何勇教授：第三代EGFR TKI奥希替尼的一线使用经验探讨

2019-08-11

gao_jian4217 (审核中...)

前往app查看评论内容

#EGFR TKI#

CLIN CANCER RES：MERTK抑制剂联合EGFR TKI治疗非小细胞肺癌

2019-11-06

gao_jian4217 (审核中...)

前往app查看评论内容

#EGFR TKI#

【2018WCLC】逆转耐药，EGFR TKIs耐药后联用阿帕替尼的临床价值再探索

2018-10-27

gao_jian4217 (审核中...)

前往app查看评论内容

#EGFR TKI#

Brit J Cancer：转移性肾细胞癌免疫组合治疗后VEGFR TKI治疗效果研究

2018-08-02

gao_jian4217 (审核中...)

前往app查看评论内容

#EGFR TKI#

韩宝惠教授：三代EGFR TKI奥希替尼防控肺癌脑转移效果显著

2019-05-16

gao_jian4217 (审核中...)

前往app查看评论内容

#EGFR TKI#

【CSCO看点】中国晚期NSCLC EGFR TKI耐药后T790M 突变率知多少？

2018-02-26

gao_jian4217 (审核中...)

前往app查看评论内容

#EGFR TKI#

[WCLC2017]大咖圆桌会：多学科专家共话肺癌EGFR TKI靶向治疗热点

2018-08-25

gao_jian4217 (审核中...)

前往app查看评论内容

#EGFR TKI#

T790M突变检测，实现EGFR TKI耐药患者的精准治疗

2018-04-16

gao_jian4217 (审核中...)

前往app查看评论内容

#EGFR TKI#

JCO：香港中文大学莫树锦对比分析EGFR TKI药物一二线治疗情况

2013-11-04

科室
- - 订阅+
  - 更多科室
工具
服务